Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | TNKS | O95271 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966228 | 0.97 | — | — | |
| SCHEMBL2340 | 0.97 | — | — | |
| SCHEMBL2341 | 0.97 | — | — | |
| SCHEMBL27861093 | 0.94 | — | — | |
| SCHEMBL27499452 | 0.94 | MAOB (0.55) | MAOBALDH1A1TSHRLMNANFE2L2 | |
| Water SCHEMBL28448011 | 0.94 | MAOB (0.55) | MAOBALDH1A1TSHRLMNANFE2L2 | |
| SCHEMBL28627434 | 0.94 | MAOB (0.55) | MAOBALDH1A1TSHRLMNANFE2L2 | |
| SCHEMBL8428975 | 0.94 | MAOB (0.55) | MAOBALDH1A1TSHRLMNANFE2L2 | |
| SCHEMBL28440624 | 0.89 | MAOB (0.50) | MAOBALDH1A1TSHRLMNANFE2L2 | |
| SCHEMBL17002705 | 0.89 | MAOB (0.50) | MAOBALDH1A1TSHRLMNANFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4281436-A1 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | BASF SE (DE) | 2023-11-29 | — | — | EP | claimed |
| WO-2022157106-A1 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | BASF SE (DE) | 2022-07-28 | — | — | WO | claimed |
| CN-107488089-A | Have axial chirality and the high optical activity allenic compound and its construction method of central chirality and application concurrently | 浙江大学 | 2017-12-19 | — | — | CN | claimed |
| US-20260125392-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-10 | — | — | US | disclosed |
| WO-2025074997-A1 | CONDENSED HETEROCYCLIC DERIVATIVE HAVING VIRAL PROLIFERATION INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2025-04-10 | — | — | WO | disclosed |
| US-20250092056-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2025-03-20 | — | — | US | disclosed |
| CN-115244063-B | Ligands for transition metal catalysts | 罗特格斯新泽西州立大学 | 2025-03-07 | — | — | CN | disclosed |
| EP-4506342-A1 | URACIL DERIVATIVE HAVING VIRAL GROWTH INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi & Co., Ltd (JP) | 2025-02-12 | — | — | EP | disclosed |
| CN-115850249-A | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2023-03-28 | — | — | CN | disclosed |
| EP-4122926-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Shionogi & Co., Ltd (JP) | 2023-01-25 | — | — | EP | disclosed |
| CN-115244063-A | Ligands for transition metal catalysts | 罗特格斯新泽西州立大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-115038696-A | Triazine derivatives having virus proliferation inhibitory activity and pharmaceutical composition containing the same | 盐野义制药株式会社 | 2022-09-09 | — | — | CN | disclosed |
| WO-2022157106-A1 | SYNTHESIS OF POLYFLUORINATED ARYL AND HETEROARYL CARBOXAMIDES | BASF SE (DE) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022138987-A1 | TRIAZINE DERIVATIVE HAVING VIRUS PROPAGATION INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 塩野義製薬株式会社 | 2022-06-30 | — | — | WO | disclosed |
| WO-2021142281-A1 | LIGANDS FOR TRANSITION METAL CATALYSTS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-07-15 | — | — | WO | disclosed |
| CN-107531698-A | With the active fused bicyclic heteroaryl group derivative as PHD inhibitor | 武田药品工业株式会社 | 2018-01-02 | — | — | CN | disclosed |
| CN-107488089-A | Have axial chirality and the high optical activity allenic compound and its construction method of central chirality and application concurrently | 浙江大学 | 2017-12-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125392-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SARS1, ACE, RNGTT | MAOB 1094/4885ALDH1A1 2694/4885TSHR 2539/4885 |
| US-20250092056-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE, SARS1, RNASEL | MAOB 458/4885ALDH1A1 1966/4885TSHR 2531/4885 |
| US-12559474-B2 | Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | NSUN2, ZC3HAV1, IFNAR1 | MAOB 2531/4885ALDH1A1 4040/4885TSHR 1137/4885 |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SARS1, ACE, ACE2 | MAOB 1526/4885ALDH1A1 2836/4885TSHR 3839/4885 |
| US-20260125365-A1 | TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACE2, ACE, SARS1 | MAOB 2044/4885ALDH1A1 4080/4885TSHR 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.